CLINICAL_TRIALS
trial_result
· 2012-12-13
Clinical Trial Update: Effect of LY2062430 on the Progression of Alzheimer's Disease [Phase 3]
Summary
A Phase 3 trial evaluating LY2062430 for progression in Alzheimer's disease has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Alzheimer's Disease | Phase 3 | Status: COMPLETED